Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cellectar Biosciences (CLRB) stocks in Canada

Learn how to easily invest in Cellectar Biosciences stocks.

Cellectar Biosciences is a biotechnology business based in the US. Cellectar Biosciences stocks (CLRB.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.27 – a decrease of 15.74% over the previous week. Cellectar Biosciences employs 11 staff and has a market cap (total outstanding stock value) of $42.7 million.

How to buy shares in Cellectar Biosciences

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CLRB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cellectar Biosciences stock price (NASDAQ:CLRB)

Use our graph to track the performance of CLRB stocks over time.

Cellectar Biosciences shares at a glance

Information last updated 2022-01-17.
Latest market close$0.59
52-week range$0.58 - $2.98
50-day moving average $0.74
200-day moving average $1.06
Wall St. target price$5.58
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.46

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Cellectar Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cellectar Biosciences price performance over time

Historical closes compared with the close of $0.5898 from 2022-01-20

1 week (2022-01-14) -15.74%
1 month (2021-12-21) -11.97%
3 months (2021-10-21) -35.89%
6 months (2021-07-21) -47.81%
1 year (2021-01-21) -69.60%
2 years (2020-01-21) -77.91%
3 years (2019-01-18) 2.02
5 years (2017-01-20) 1.28

Cellectar Biosciences financials

Gross profit TTM $0
Return on assets TTM -43.91%
Return on equity TTM -79.62%
Profit margin 0%
Book value $0.61
Market capitalisation $42.7 million

TTM: trailing 12 months

Cellectar Biosciences share dividends

We're not expecting Cellectar Biosciences to pay a dividend over the next 12 months.

Have Cellectar Biosciences's shares ever split?

Cellectar Biosciences's shares were split on a 1:10 basis on 16 July 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellectar Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cellectar Biosciences shares which in turn could have impacted Cellectar Biosciences's share price.

Cellectar Biosciences share price volatility

Over the last 12 months, Cellectar Biosciences's shares have ranged in value from as little as $0.5816 up to $2.98. A popular way to gauge a stock's volatility is its "beta".

CLRB.US volatility(beta: 1.56)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectar Biosciences's is 1.559. This would suggest that Cellectar Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cellectar Biosciences overview

Cellectar Biosciences, Inc. , a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; and IntoCell Inc. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Stocks similar to Cellectar Biosciences

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site